Læknablaðið - 01.09.2022, Síða 34

410 L ÆKNABL AÐIÐ 2022/108
Y F I R L I T S G R E I N
Heimildir
1. Voineskos D Daskalakis ZJ, Blumberger DM. Management of Treatment-Resistant
Depression: Challenges and Strategies. Neuropsychiatr Dis Treat 2020; 16: 221-34.
2. COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy
as adjunct to SSRI antidepressants in open-label treatment-resistant depression study.
2021. globenewswire.com/newsrelease/2021/12/13/2350636/0/en/COMPASS-Pathways-
announces-positive-outcome-of-25mg-COMP360- psilocybin-therapy-as-adjunct-to-SSRI-
-antidepressants-in-open-label-treatment-resistant-depression-study.html - apríl 2022
3. COMPASS Pathways announces positive topline results from groundbreaking phase IIb
trial of investigational COMP360 psilocybin therapy for treatment-resistant depression.
compasspathways.com/positive-topline-results - mars 2022.
4. Richards D. Prevalence and clinical course of depression: a review. Clin Psychol Rev 2011;
31: 1117-25.
5. Hasin DS, Sarvet AL, Meyers J, et al. Epidemiology of Adult DSM-5 Major Depressive
Disorder and Its Specifiers in the United States. JAMA Psychiatry 2018; 75: 336-46.
6. Greenberg PE, Fournier AA, Sisitsky T, et al. The economic burden of adults with major
depressive disorder in the United States (2005 and 2010). J Clin Psychiatry 2015; 76: 155-62.
7. GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12
mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the
Global Burden of Disease Study 2019. Lancet Psychiatry 2022; 9: 137-50.
8. World Health Organization. The ICD-10 classification of mental and behavioural dis-
orders. World Health Organization, Genf 2004.
9. World Health Organization. ICD-10 Classifications of Mental and Behavioural Disorder:
Clinical Descriptions and Diagnostic Guidelines. World Health Organization, Genf 1992.
10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders
: DSM-5. American Psychiatric A, American Psychiatric Association DSMTF. American
Psychiatric Association, Arlington 2013.
11. Cain RA. Navigating the Sequenced Treatment Alternatives to Relieve Depression
(STAR*D) study: practical outcomes and implications for depression treatment in primary
care. Prim Care 2007; 34: 505-19, vi.
12. Berlim MT, Fleck MP, Turecki G. Current trends in the assessment and somatic treatment
of resistant/refractory major depression: an overview. Ann Med 2008; 40: 149-59.
13. Heerlein K, Perugi G, Otte C, et al. Real-world evidence from a European cohort study of
patients with treatment resistant depression: Treatment patterns and clinical outcomes. J
Affect Disord 2021; 290: 34-44.
14. Pandarakalam JP. Challenges of Treatment-resistant Depression. Psychiatr Danub 2018; 30:
273-84.
15. American Psychiatric Association. The Practice of Electroconvulsive Therapy. Second
Edition ed. American Psychiatric Association, Arlington 2001: 368.
16. Levey DF, Stein MB, Wendt FR, et al. Bi-ancestral depression GWAS in the Million Veteran
Program and meta-analysis in >1.2 million individuals highlight new therapeutic direct-
ions. Nat Neurosci 2021; 24: 954-63.
17. Kellner CH, Popeo DM, ALoysi AS. Electroconvulsive Therapy for Catatonia. Am J
Psychiatry 2010; 167: 1127-8; author reply 8.
18. Lee HJ, Kim SM, Kwon JY. Repetitive transcranial magnetic stimulation treatment for per-
ipartum depression: systematic review & meta-analysis. BMC Pregnancy Childbirth 2021;
21: 118.
19. Lefaucheur JP, Aleman A, Baeken C, et al. Evidence-based guidelines on the therapeutic
use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). Clin
Neurophysiol 2020; 131: 474-528.
20. Johnston KM, Powell LC, Anderson IM, et al. The burden of treatment-resistant
depression: A systematic review of the economic and quality of life literature. J Affect
Disord 2019; 242: 195-210.
21. Johns Hopkins opening a new psychedelic research center, studying use of ‘magic
mushrooms’ and more. nytimes.com/2019/09/04/science/psychedelic-drugs-hopkins-
-depression.html - ágúst 2022..
22. COMPASS news: COMPASS Pathways joins forces with King’s College London and South
London and Maudsley NHS Foundation Trust to accelerate psychedelic research and
develop new models of mental health care in the UK. 2021. compasspathways.com/kings-
-college-london-south-london-and-maudsley - apríl 2022.
23. Gukasyan N, Davis AK, Barrett FS, et al. Efficacy and safety of psilocybin-assisted treat-
ment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol
2022; 36: 151-8.
24. Carod-Artal FJ. Hallucinogenic drugs in pre-Columbian Mesoamerican cultures.
Neurologia 2015; 30: 42-9.
25. Hofmann A. Psychotomimetic agents. Í : Burger A, ritstj. Drugs affecting the central ner-
vous system. Marcel Dekker, New York 1968: 169-235.
26. Aboul-Enein HY. Psilocybin: a pharmacological profile. Am J Pharm Sci Support Public
Health 1974; 146: 91-5.
27. Metzner R. Sacred Mushroom of Visions: Teonanácatl: A Sourcebook on the Psilocybin
Mushroom. Park Street Press, Vermont 2005: 293.
28. Nichols DE. Hallucinogens. Pharmacol Ther 2004; 101: 131-81.
29. Daniel J, Haberman M. Clinical potential of psilocybin as a treatment for mental health
conditions. Ment Health Clin 2018; 7: 24-8.
30. Hasler F, Grimberg U, Benz MA, et al. Acute psychological and physiological effects
of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study.
Psychopharmacology (Berl) 2004; 172: 145-56.
31. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J
Psychopharmaco 2008; 22: 603-20.
32. Hasler F, Bourquin D, Brenneisen R, et al. Determination of psilocin and 4-hydroxyindole-
-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intraven-
ous psilocybin in man. Pharm Acta Helv 1997; 72: 175-84.
33. Horita A, Weber LJ. Dephosphorylation of Psilocybin to Psilocin by Alkaline Phosphatase.
Proc Soc Exp Biol Med 1961; 106: 32-4.
34. Anastos N, Barnett NW, Pfeffer FM, et al. Investigation into the temporal stability of
aqueous standard solutions of psilocin and psilocybin using high performance liquid
chromatography. Sci Justice 2006; 46: 91-6.
35. Hopf A, Eckert H. Distribution patterns of 14-C-psilocin in the brains of various animals.
Act Nerv Super (Praha) 1974; 16: 64-6.
36. Madsen MK, Fisher PM, Burmester D, et al. Psychedelic effects of psilocybin correlate
with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacol
2019; 44: 1328-34.
37. Coull JT, Cheng RK, Meck WH. Neuroanatomical and neurochemical substrates of timing.
Neuropsychopharmacol 2011; 36: 3-25.
38. Passie T, Seifert J, Schneider U, et al. The pharmacology of psilocybin. Addict Biol 2002; 7:
357-64.
39. Smith WR, Sisti D. Ethics and ego dissolution: the case of psilocybin. J Med Ethics 2021; 47:
807.
40. Roseman L, Nutt DJ, Carhart-Harris R.L. Quality of Acute Psychedelic Experience Predicts
Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Front Pharmacol
2017; 8: 974.
41. Kraehenmann R, Preller KH, Scheidegger M, et al. Psilocybin-Induced Decrease in
Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Biol
Psychiatry 2015; 78: 572-81.
42. Goldberg SB, Pace BT, Nicholas CR, et al. The experimental effects of psilocybin on
symptoms of anxiety and depression: A meta-analysis. Psychiatry Res 2020; 284: 112749.
43. Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for
Depression. N Engl J Med 2021; 384: 1402-11.
44. COMP360 psilocybin therapy for treatment-resistant depression: Phase IIb topline data
2021. j8g9v7z6.rocketcdn.me/wp-content/uploads/2021/11/COMP001_-_topline_data.pdf -
mars 2022.
45. Carbonaro TM, Bradstreet MP, Barrett FS, et al. Survey study of challenging experiences
after ingesting psilocybin mushrooms: Acute and enduring positive and negative
consequences. J Psychopharmacol 2016; 30: 1268-78.
46. Erritzoe D, Roseman L, Nour MM, et al. Effects of psilocybin therapy on personality
structure. Acta Psychiatr Scand 2018; 138: 368-78.
47. de Veen BT, Schellekens AF, Verheij MM, et al. Psilocybin for treating substance use dis-
orders? Expert Rev Neurother 2017; 17: 203-12.
48. Nielsen SM, Toftdahl NG, Nordentoft M, et al. Association between alcohol, cannabis,
and other illicit substance abuse and risk of developing schizophrenia: a nationwide
population based register study. Psychol Med 2017; 47: 1668-77.
49. Griffiths RR, Richards WA, McCann U, et al. Psilocybin can occasion mystical-type
experiences having substantial and sustained personal meaning and spiritual significance.
Psychopharmacology 2006; 187: 268-83; discussion 84-92.
50. Carhart-Harris RL, Nutt DJ. User perceptions of the benefits and harms of hallucinogenic
drug use: A web-based questionnaire study. J Substance Use 2010; 15: 283-300.
51. About Psilocybin Therapy. compasspathways.com/our-research/psilocybin-therapy/about-
psilocybintherapy - mars 2022.
52. Treatment-resistant Depression. compasspathways.com/our-research/psilocybin-therapy/
clinical-trials/treatment-resistant-depression - mars 2022.
53. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br
J Psychiatry 1979; 134: 382-9.
54. European Medicines Agency. Guideline on clinical investigation of medicinal products in
the treatment of depression. 2013.
55. Segal A, Sisti D. Research Moratoria and Off-Label Use of Ketamine. Am J Bioeth 2016; 16:
60-1.
56. Spravato. ema.europa.eu/en/documents/product-information/spravato-epar-product-in-
form ation_en.pdf - apríl 2022.
57. Lowe H, Toyang N, Steele B, et al. The Therapeutic Potential of Psilocybin. Molecules 2021;
26: 2948.
58. Kellner CH, Greenberg RM, Murrough JW, et al. ECT in treatment-resistant depression.
Am J Psychiatry 2012; 169: 1238-44.
59. Berg JW, Appelbaum PS, Lidz CW, et al. Informed Consent: Legal Theory and Clinical
Practice. 2nd Edition. Oxford University Press, Fair Lawn, New Jersey 2001.
60. Quilty LC, Meusel LA, Bagby RM. Neuroticism as a mediator of treatment response to
SSRIs in major depressive disorder. J Affect Disord 2008; 111: 67-73.